Clinics in Dermatology
Volume 26, Issue 5 , Pages 417-418 , September 2008

Treatment of psoriasis: a journey from empiricism to evidence

  • Michael P. Schön, MD

      Affiliations

    • Corresponding Author InformationDepartment of Dermatology and Venereology, Georg August University, Von-Siebold-Str. 3, 37075 Göttingen, Germany.

References 

  1. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–1674
  2. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–1684
  3. Smith G, Wilkie MJ, Deeni YY. Melanocortin 1 receptor (MC1R) genotype influences erythemal sensitivity to psoralen-ultraviolet A photochemotherapy. Br J Dermatol. 2007;157:1230–1234
  4. Akman A, Dicle O, Yilmaz F, Coksun M, Yilmaz F. Discrepant levels of vascular endothelial growth factor in psoriasis patients treated with PUVA, Re-PUVA and narrow-band UVB. Photodermatol Photoimmunol Photomed. 2008;24:123–127
  5. Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25:529–534
  6. Kingo K, Mössner R, Köks S, et al. Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis. Br J Dermatol. 2007;156:646–652
  7. Schmid-Ott G, Schallmayer S, Calliess IT. Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience. Clin Dermatol. 2007;25:547–554

PII: S0738-081X(08)00123-5

doi: 10.1016/j.clindermatol.2008.07.002

Clinics in Dermatology
Volume 26, Issue 5 , Pages 417-418 , September 2008

Article Tools